Table 2.

Nomograms on prediction of pathologic stage in men treated with radical prostatectomy for clinically localized prostate cancer

Study	Prediction model	Outcome measure	No of Patients	Variables	Discrimination
Partin et al59	Probability table	Pathologic stage	703/4133	Biopsy GS, CS, PSA	Internal: 72% External: 84%
Epstein et al7	Risk group	Clinically indolent cancer defined as pathologically organ confined, tumor volume ≤0.2 cc, GS < 7	157	Biopsy GS, millimeter core with cancer, PSAD, no adverse pathologic findings on needle biopsy	NA
Kattan et al8	Probability nomogram development	Clinically indolent cancer defined as pathologically organ confined, tumor volume ≤0.5 cc, no GG 4 or 5	409	PSA, primary and secondary biopsy GS, volume, millimeter core with cancer, millimeter core without cancer	64%
Chun et al60	Probability nomogram development	Gleason upgrading between biopsy and RP	2982	PSA, CS, primary and secondary Biopsy GS	80%
Chun et al61	Probability nomogram development	Significant Gleason upgrading between biopsy and RP	4789	PSA, CS, biopsy GS	76%
Ackerman et al62	Probability formula	Surgical margin positivity	107	Number positive sextant cores, PSAD	70%
Bostwick et al63	Probability graph	Capsular penetration	314	Biopsy GS, Percent cancer in biopsy cores, PSA	78%
Gamito et al64	Neural network	Capsular penetration	4133	Age, race, PSA, PSAV, GS, CS	30–76%
Gilliland et al65	Probability graph	ECE	3826	Age, biopsy GS, PSA	63%
Steuber et al39	Probability nomogram development	Side-specific ECE	1118	PSA, CS, biopsy GS, percent Positive cores, percent of cancer in positive cores	84%
Baccala et al66	Probability nomogram development	SV invasion	6740	Age, PSA, Biopsy GS, CS	80%
Gallina et al67	Probability nomogram development	SV invasion	896	PSA, CS, biopsy GS, percent positive biopsy cores	79%
Bluestein et al68	Probability graph	LN invasion assessed with limited pelvic lymphadenectomy	816	Biopsy GS, CS, PSA	82%
Batuello et al69	Neural network	LN invasion assessed with limited pelvic lymphadenectomy	6454	Biopsy GS, CS, PSA	77–81%
Briganti et al70	Probability nomogram development	LN assessed with extended pelvic lymphadenectomy (≥10 nodes)	602	PSA, CS, biopsy GS	76%
Kim et al50	Probability nomogram development	LN invasion assessed with extended pelvic lymphadenectomy	541	PSA, CS, GS	Internal: 88.3% External: NA

GS, Gleason sum; CS, clinical stage; PSA, prostate specific antigen; PSAD, prostate specific antigen density; GG, Gleason grade; RP, radical prostatectomy; PSAV, prostate specific antigen velocity; ECE, extracapsular extension; SV, seminal vesicle; LN, lymph node; NA, not available.